Ask AI
ProCE Banner Activity

OptiTROP-Breast05: Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) in the 1L Treatment of Unresectable Locally Advanced/Metastatic TNBC

Conference Coverage
Slideset

In the phase II OptiTROP-Breast05 study, sacituzumab tirumotecan (sac-TMT) demonstrated promising antitumor activity in patients with unresectable locally advanced or metastatic TNBC independent of PD-L1 status.

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.